Company No: 13542017 (England and Wales)

Contents

• Company Information
• Accountants' Report
• Balance Sheet
• Notes to the Financial Statements

Directors	R Marais
	P J Masterson (Resigned 15 January 2026)
	C Springer

Registered office	The Heath Business And Technical Park
	Runcorn
	WA7 4QX
	United Kingdom

Company number

13542017 (England and Wales)

Accountant	Kreston Reeves LLP
	Suite 2
	Orchard House
	Orchard Street
	Canterbury
	Kent
	CT2 8AR

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Oncodrug Ltd for the financial period ended 31 March 2026 which comprise the Balance Sheet and the related notes 1 to 8 from the Company’s accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at www.icaew.com/regulation.

This report is made solely to the Board of Directors of Oncodrug Ltd, as a body, in accordance with the terms of our engagement letter dated 15 January 2026. Our work has been undertaken solely to prepare for your approval the financial statements of Oncodrug Ltd and state those matters that we have agreed to state to the Board of Directors of Oncodrug Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Oncodrug Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Oncodrug Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Oncodrug Ltd. You consider that Oncodrug Ltd is exempt from the statutory audit requirement for the financial period.

We have not been instructed to carry out an audit or a review of the financial statements of Oncodrug Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Kreston Reeves LLP

Suite 2
Orchard House
Orchard Street
Canterbury
Kent
CT2 8AR

05 October 2026

	Note	31.03.2026		31.08.2025
		£		£
Fixed assets
Tangible assets	3	113,993		98,304
		113,993		98,304
Current assets
Debtors	4	949,145		975,231
Cash at bank and in hand		660,901		1,820,037
		1,610,046		2,795,268
Creditors: amounts falling due within one year	5	( 64,360)		( 119,170)
Net current assets		1,545,686		2,676,098
Total assets less current liabilities		1,659,679		2,774,402
Creditors: amounts falling due after more than one year	6	( 1,100,000)		( 1,100,000)
Net assets		559,679		1,674,402
Capital and reserves
Called-up share capital	7	211		211
Profit and loss account		559,468		1,674,191
Total shareholders' funds		559,679		1,674,402

For the financial period ending 31 March 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• The members have not required the Company to obtain an audit of its financial statements for the financial period in accordance with section 476;
• The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
• These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Oncodrug Ltd (registered number: 13542017) were approved and authorised for issue by the Board of Directors on 07 October 2026. They were signed on its behalf by:

C Springer Director

1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Oncodrug Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is The Heath Business And Technical Park, Runcorn, WA7 4QX, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Reporting period length

The company has changed its accounting period date, resulting in the current period covering 7 months to 31 March 2026 (prior period: 12 months to 31 August 2025). Comparatives are therefore not fully comparable. The change was made to align the Companies year end with the fiscal year.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery	5 years straight line
Office equipment	5 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Leases

The Company as lessee
Assets held under finance leases, hire purchase contracts and other similar arrangements, which confer rights and obligations similar to those attached to owned assets, are capitalised as tangible fixed assets at the fair value of the leased asset (or, if lower, the present value of the minimum lease payments as determined at the inception of the lease) and are depreciated over the shorter of the lease terms and their useful lives. The capital elements of future lease obligations are recorded as liabilities, while the interest elements are charged to the Profit and Loss Account over the period of the leases to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

2. Employees

	Period from 01.09.2025 to 31.03.2026		Year ended 31.08.2025
	Number		Number
Monthly average number of persons employed by the Company during the period, including directors	15		16

3. Tangible assets

	Plant and machinery		Office equipment		Total
	£		£		£
Cost
At 01 September 2025	32,542		139,095		171,637
Additions	35,507		2,888		38,395
At 31 March 2026	68,049		141,983		210,032
Accumulated depreciation
At 01 September 2025	4,865		68,468		73,333
Charge for the financial period	6,285		16,420		22,705
At 31 March 2026	11,150		84,889		96,039
Net book value
At 31 March 2026	56,899		57,094		113,993
At 31 August 2025	27,677		70,627		98,304

4. Debtors

	31.03.2026		31.08.2025
	£		£
Trade debtors	840		129,107
Prepayments and accrued income	146,864		211,160
VAT recoverable	9,516		66,018
Corporation tax	708,586		485,607
Other debtors	83,339		83,339
	949,145		975,231

5. Creditors: amounts falling due within one year

	31.03.2026		31.08.2025
	£		£
Trade creditors	54,033		104,184
Accruals	6,500		12,000
Other creditors	3,827		2,986
	64,360		119,170

6. Creditors: amounts falling due after more than one year

	31.03.2026		31.08.2025
	£		£
Other creditors	1,100,000		1,100,000

There are no amounts included above in respect of which any security has been given by the small entity.

7. Called-up share capital

	31.03.2026		31.08.2025
	£		£
Allotted, called-up and fully-paid
211,000 Ordinary shares of £ 0.001 each	211		211

8. Ultimate controlling party

In the opinion of the directors there is no controlling party.